Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Asana Inc. (ASAN) vs Eli Lilly And Co (LLY) Price & Performance

Asana Inc.Trade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Asana Inc. vs Eli Lilly And Co — how do they compare? Asana Inc. trades at $9.05 (market cap $2.13B), while Eli Lilly And Co trades at $1,218.75 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 507× Asana Inc.'s market cap, and Eli Lilly And Co pays a 0.57% dividend while Asana Inc. pays none. Which is the better fit depends on your goals.

ASANLLY
Market Cap
$2.13B$1.08T
Sector
Consumer CyclicalHealth
52-Week High
$15.19$1.24K
52-Week Low
$5.46$639.43
Enterprise Value
$1.96B$1.13T
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Asana Inc.

Asana (ASAN) trades at $9.065, down 1.79% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Revenue growth is strong, reaching $723.88M in 2025, yet the company remains unprofitable with a net income margin of -20.21%. Recent earnings beats and AI product developments, including the StackAI acquisition, highlight operational momentum amid competitive pressures.

The outlook is mixed: analyst consensus leans neutral with a $10.33 price target, suggesting modest upside, but persistent losses and high valuation ratios pose risks. Key catalysts include continued AI integration and FedRAMP authorization, while decelerating revenue growth and competition from tech giants remain headwinds for shareholder value.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.

Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Asana Inc.

Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.

Read more on ASAN

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY